PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY
CMD
CMD was delisted on the 24th of August, 2016.
3 hedge funds and large institutions have $2.46M invested in PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
8% more capital invested
Capital invested by funds: $2.29M → $2.46M (+$174K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$109K |
| 2 |
Jane Street
New York
|
+$3.22K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$2.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18K |
CMD Hedge Fund Activity: Q4 2013 in Review
3 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY (CMD) for Q4 2013, worth a combined $2.46M — up 7.6% from $2.29M a quarter earlier.
Fund positioning in CMD was balanced in Q4 2013: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $109K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $18K sold.
- 3 institutional investors held PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY (CMD) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $2.46M of PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY stock for Q4 2013, up 7.6% quarter-over-quarter.
- 1 fund opened new PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY positions in Q4 2013 and 1 closed out, a net change of 0 holders.
- The largest PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY buyer in Q4 2013 was Goldman Sachs, an estimated $109K added.
- The largest PROSHARES TR II ULTRASHORT BLOOMBERG COMMODITY seller in Q4 2013 was Tower Research Capital (TRC), an estimated $18K sold.
Based on aggregated 13F filings for Q4 2013.